Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant neoplasm involving the biliary tree
Biomarker and diagnostic research for biliary tract cancer has been reported in the published literature.
2 FDA-approved treatments are available for biliary tract cancer, including DURVALUMAB (IMFINZI, approved 2017) and ZANIDATAMAB-HRII (ZIIHERA, approved 2024). An additional 13 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
144 clinical trials registered, 40 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE4, 12 PHASE3, 62 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04999761](https://clinicaltrials.gov/study/NCT04999761) |
Data assembled from 4 of 12 sources · Last updated Nov 3, 2026, 3:00 PM UTC
Genetic and Rare Diseases Info Center
ZIIHERA |
ZANIDATAMAB-HRII |
— |
2024 |
Available |
IMFINZI | DURVALUMAB | — | 2017 | Available |
The following drugs have received orphan drug designation from the FDA for biliary tract cancer. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
humanized IgG1 monoclonal antibody against annexin-A1 | humanized IgG1 monoclonal antibody against annexin-A1 | Medannex Ltd | 2025 | — | Designated |
trastuzumab-rezetecan | trastuzumab-rezetecan | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 2023 | — | Designated |
Spiro[3H-Indole-3,2¿-pyrrolidin]-2(1H)-one derivative | Spiro[3H-Indole-3,2¿-pyrrolidin]-2(1H)-one derivative | Boehringer Ingelheim Pharmaceuticals, Inc. | 2023 | — | Withdrawn |
Mefuparib Hydrochloride Tablets | Mefuparib Hydrochloride Tablets | Convalife (Shanghai) Co., Ltd. | 2023 | — | Designated |
Nanvuranlat | Nanvuranlat | J-Pharma Co., Ltd. | 2022 | — | Designated |
Silmitasertib | Silmitasertib | Senhwa Biosciences, Inc. | 2022 | — | Designated |
Envafolimab | Envafolimab | 3D Medicines (Sichuan) Co., Ltd | 2020 | — | Designated |
fosgemcitabine palabenamide | fosgemcitabine palabenamide | NuCana plc | 2019 | — | Withdrawn |
etoposide toniribate | etoposide toniribate | CellAct Pharma GmbH | 2019 | — | Designated |
transforming growth factor beta trap/anti-programmed death ligand-1 antibody bifunctional fusion protein | transforming growth factor beta trap/anti-programmed death ligand-1 antibody bifunctional fusion protein | EMD Serono Research & Development Institute, Inc. | 2018 | — | Withdrawn |
sodium 2-hydroxylinoleate | sodium 2-hydroxylinoleate | Ability Pharmaceuticals, SL | 2018 | — | Designated |
merestinib | merestinib | Eli Lilly and Company | 2017 | — | Designated |
varlitinib | varlitinib | ASLAN Pharmaceuticals Pte, Ltd. | 2015 | — | Designated |
Gene therapy approaches for biliary tract cancer have been reported in the published literature.
144 trials found
AB122 Platform Study |
PHASE1 |
Taiho Pharmaceutical Co., Ltd. |
RECRUITING |
[NCT06564623](https://clinicaltrials.gov/study/NCT06564623) | Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) | PHASE1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | RECRUITING |
[NCT06731998](https://clinicaltrials.gov/study/NCT06731998) | Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery | NA | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | RECRUITING |
[NCT06293898](https://clinicaltrials.gov/study/NCT06293898) | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | PHASE1 | SystImmune Inc. | RECRUITING |
[NCT07025174](https://clinicaltrials.gov/study/NCT07025174) | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer | PHASE2 | First Affiliated Hospital of Zhejiang University | RECRUITING |
469 publications have been identified in PubMed for biliary tract cancer. Research spans Review / Meta-Analysis (31%), Clinical Trial Publication (21%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 146 | 31% |
Clinical study results | 100 | 21% |
Disease patterns and progression | 69 | 15% |
Laboratory research | 55 | 12% |
Testing and diagnosis research | 47 | 10% |
Patient case studies | 18 | 4% |
New treatment approaches | 18 | 4% |
Other research | 16 | 3% |
Neureiter D (2026). [PMID: 41287511](https://pubmed.ncbi.nlm.nih.gov/41287511/). *Expert review of anticancer therapy*. [Review / Meta-Analysis]
Mangiavillano B (2026). [PMID: 40695478](https://pubmed.ncbi.nlm.nih.gov/40695478/). *Endoscopy*. [Epidemiology / Natural History]
Zhu Y (2026). [PMID: 41912087](https://pubmed.ncbi.nlm.nih.gov/41912087/). *J Hepatol*. [Basic Science / Preclinical]
Erul E (2026). [PMID: 42087549](https://pubmed.ncbi.nlm.nih.gov/42087549/). *Expert Rev Mol Diagn*. [Review / Meta-Analysis]
Kosaka H (2026). [PMID: 41966637](https://pubmed.ncbi.nlm.nih.gov/41966637/). *J Gastroenterol*. [Epidemiology / Natural History]
Xu W (2026). [PMID: 41932868](https://pubmed.ncbi.nlm.nih.gov/41932868/). *Cell Death Dis*. [Basic Science / Preclinical]
Eaton DJ (2026). [PMID: 41512568](https://pubmed.ncbi.nlm.nih.gov/41512568/). *Clin Oncol (R Coll Radiol)*. [Clinical Trial Publication]
Takaoka S (2026). [PMID: 42059478](https://pubmed.ncbi.nlm.nih.gov/42059478/). *Jpn J Clin Oncol*. [Epidemiology / Natural History]
Lang H (2026). [PMID: 41537967](https://pubmed.ncbi.nlm.nih.gov/41537967/). *Chirurgie (Heidelb)*. [Review / Meta-Analysis]
Yoon J (2026). [PMID: 41297674](https://pubmed.ncbi.nlm.nih.gov/41297674/). *J Hepatol*. [Clinical Trial Publication]
AI-curated news mentioning biliary tract cancer
Updated Oct 5, 2026
A new study evaluates minimal residual disease (MRD) and longitudinal monitoring of biliary tract cancer using a customized circulating tumor DNA (ctDNA) panel. This research could enhance post-surgery monitoring strategies for patients with this challenging cancer type.
Compass Therapeutics will proceed with its FDA application for a drug targeting advanced biliary tract cancer, despite the FDA's request for a new clinical study. The company emphasizes the urgent need for treatment options in this patient population.
A new study explores the molecular subtyping of biliary tract neuroendocrine carcinomas, highlighting key clinicopathological features and their prognostic implications. This research could inform future therapeutic strategies for this rare cancer type.
Recent deep molecular profiling of biliary tract cancer reveals new biological mechanisms and potential therapeutic targets. This research could pave the way for innovative treatment strategies in a challenging cancer type.